In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite

Antiviral Research

Volumn 32, Issue 2, 1996, Pages 81-89

  Chaput, Alan J ^a   D'Ambrosio, Robin ^a   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bisheteroarylpiperazine; Delavirdine; HIV; Pharmacokinetics; Protein binding; Reverse transcriptase inhibitor

Indexed keywords

ALBUMIN; DELAVIRDINE; DRUG METABOLITE; IMMUNOGLOBULIN; OROSOMUCOID; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 0030270023     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00984-1     Document Type: Article

References (21)

1. Boudinot, F.D. and Jusko, W.J. (1984) Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J. Pharm. Sci. 73, 774-780.
2. Bourgoignie, J.J., Meneses, R., Ortiz, C. et al. (1988) The clinical spectrum of renal disease associated with human immunodeficiency virus. Am. J. Kidney Dis. 12, 131-137.
3. Bussel, J.B. and Haimi, J.S. (1988) Isolated thrombocytopenia in patients infected with HIV: treatment with intravenous gamma globulin. Am. J. Hematol. 28, 79-84.
4. Chlebowski, R.T., Grosvenor, M.B., Bernhard, N.H. et al. (1989) Nutritional status, gastrointestinal disfunction, and survival in patients with AIDS. Am. J. Gastroenterol. 84, 1288-1293.
5. Dueweke, T.J., Poppe, S.M., Romero, D.L. et al. (1993) U-90152, a potent inhibitor of human immunodeficiency virus type-1 replication. Antimicrob. Agents Chemother. 37, 1127-1131.
6. Freimuth, W., Davey, R., Batts, D., Lane, C., Cox, S., Wathen, L., Peel, B., Daenzer, G., Morse, G., Chaitt, D. et al. (1994) Phase II clinical trials of delavirdine mesylate combination therapy. Int. Conf. AIDS, Tokyo, Japan, Aug. 1994, 10(2):59 (abstract No. 512B).
7. Freimuth, W.W., Wathen, L.K., Cox, S.R., Chuang-Stein, C.J., Greenwald, C.A., Daenzer, C.L., Wang, Y. and Delavirdine Team, Pharmacia and Upjohn (1996) Delavirdine in combination with zidovudine causes sustained antiviral and immunological effects in HIV-1 infected individuals. 3rd Conf. Retroviruses and Opportunistic Infections, Washington, DC, USA, Jan. 28-Feb. 1, 1996, p. abstract no. LB8a.
8. Morse, G., Para, M., Fischl, M., Freimuth, W. and the ACTG 260 Study Team (1995) Delavirdine dosage requirements during a concentration-targeted study. 35th ICAAC, San Francisco, USA, Sept. 17-20, 1995, abstract no. 128.
9. Howard, G.M. and Schwende, F.J. (1995) The development of HPLC-based analytical methods for delavirdine. J. Chromatogr. (in press).
10. Ingulli, E., Tejani, A., Fikrig, S. et al. (1991) Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J. Pediatr. 119, 710-716.
11. Kaplan, M.S., Wechsler, M. and Benson, M.C. (1987) Urologic manifestations of AIDS. Urology 30, 441-443.
12. Korbet, S.M. and Schwartz, M.M. (1992) Human immunodeficiency virus infection and nephrotic syndrome. Am. J. Kidney Dis. 20, 97-103.
13. Kremer, J.M.H., Wilting, J. and Janssen, L.H.M. (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40, 1-41.
14. Lane, H.C., Masur, H., Edgar, L.C. et al. (1983) Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309, 453-458.
15. Luke, D.R., Sarnoski, T.P. and Dennis, S. (1992) Incidence of microalbuminuria in ambulatory patients with acquired immunodeficiency syndrome. Clin. Nephrol. 38, 69-74.
16. MacKichan, J.J. (1992) Influence of protein binding and use of unbound (free) drug concentrations. In: W.E. Evans, J.J. Schentag and W.J. Jusko (Eds), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, pp. 5-1-5-48. Applied Therapeutics Inc., Vancouver, WA.
17. National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group (1991) Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N. Engl. J. Med. 325, 73-80.
18. Para, M.F., Fischl, M., Meehan, P., Morse, G., Wood, K., Shafer, R., Freimuth, W., Demeter, L., Holden Wiltse, J. and Nevin, T. for the ACTG 260 Study Team (1996) ACTG 260: randomized phase I/II concentration-controlled trial of the anti-HIV activity of delavirdine. 3rd Conf. Retroviruses and Opportunistic Infections, Washington, DC, USA, Jan. 28-Feb. 1, 1996, p. 163.
19. Rosser, L.M., O'Donnell, A.M., Lee, K.M. et al. (1994) In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite. Antiviral Res. 25, 193-200.
20. Singer, P., Katz, D.P., Dillon, L. et al. (1992) Nutritional aspects of the acquired immunodeficiency syndrome. Am. J. Gastroenterol. 87, 265-273.
21. Tertian, G., Risler, N., LeBras, P et al. (1987) Intravenous gamma globulin treatment for thrombocytopenia purpura in patients with human immunodeficiency virus (HIV) infection. Eur. J. Hematol. 39, 180-181.